Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 371

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 371
---
2017 – 08/28/2020 Title: Brain -enrichedmicroRNAs detectable in plasma as biomarkers of Alzheimer’s disease. The main goal of this Phase IIB study is to establish reliable pre -analyticalprotocol and analytical workflow for detection of brain -enrichedmicroRNAs in plasma of AD patients and control subjects. NIH/NIA, Grant Number 3R44AG044860 -06S1(Admin. Suppl.) 09/01/2019 – 02/28/2020 Title: Brain -enrichedmicroRNAs detectable in plasma as biomarkers of Alzheimer’s disease. Alzheimer’s Drug Discovery Foundation. Ref #: 201809 -201642511/11/2019 – 11/10/2020 Title: Circulating brain -enrichedmicroRNAs as peripheral biomarkers of neurodegeneration. The main goal of this project is to assess associations between circulating brain -enrichedmicroRNAs and known AD markers in preclinical AD samples from A4 prevention study. NIH/NIA SBIR Phase II Grant Number 2R44AG044860 -0202/15/2015 – 01/31/2017 Title: Early detection of Alzheimer’s (MCI stage): Analysis of plasma cell -freemiRNA. The goal of this Phase II study was to provide further validation for the MCI microRNA signature using plasma samples from well -characterizedheterogeneous cohorts and to define microRNA biomarker signatures for predicting AD “progressors” and for differentiating AD from other neurodegenerative diseases. 213 NIH/NIA SBIR Phase I Grant Number 1R43AG053116 -0106/01/2016 – 11/30/2016 Title: Circulating organ -enrichedmicroRNAs as biomarkers of aging The goal of this study was to analyze brain -enrichedmicroRNA signatures detectable in plasma in the context of normal aging; the study was conducted in collaboration with the New York Blood Center. Rett Syndrome Research Trust (2014 and 2015 awards) 12/01/2014 – 04/30/2016 Title: Analysis of circulating brain -enrichedmicroRNAs as biomarkers for Rett Syndrome. The goal of this study was to assess brain -enrichedmicroRNA biomarkers in plasma samples of Mecp2 deficient male and female mice and controls. NIH/NIA SBIR Phase I Grant Number